|
Market Closed -
NYSE
21:00:00 11/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 2.640 USD | -3.30% |
|
-1.12% | +46.67% |
| 08-12 | Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026 | |
| 08-12 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Business description: Protalix BioTherapeutics, Inc.
Number of employees: 226
Sales by Activity: Protalix BioTherapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology (Startups) | 38.35M | 47.64M | 65.49M | 53.4M | 52.74M |
Executive Committee: Protalix BioTherapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 59 | 29/06/2019 |
Gilad Mamlok
DFI | Director of Finance/CFO | 57 | 23/08/2025 |
Ori Kalid
CTO | Chief Tech/Sci/R&D Officer | - | 31/05/2024 |
Shoshi Tessler
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2023 |
Yaron Naos
COO | Chief Operating Officer | 62 | 28/05/2018 |
Composition of the Board of Directors: Protalix BioTherapeutics, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Amos Bar Shalev
BRD | Director/Board Member | 73 | 30/06/2008 |
Aharon Schwartz
BRD | Director/Board Member | 83 | 31/10/2014 |
Dror Bashan
BRD | Director/Board Member | 59 | 29/06/2019 |
Pol Boudes
BRD | Director/Board Member | 69 | 30/11/2019 |
Gwen Melincoff
BRD | Director/Board Member | 74 | 30/11/2019 |
Shmuel Ben Zvi
BRD | Director/Board Member | 66 | 29/06/2022 |
Eliot Forster
CHM | Chairman | 60 | 13/09/2023 |
Christian Elze
BRD | Director/Board Member | 69 | 25/06/2025 |
Company details: Protalix BioTherapeutics, Inc.
Protalix Biotherapeutics, Inc.
2 University Plaza
07601, Hackensack
+201 696 9345
http://www.protalix.com
Other Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.30% | -1.12% | +51.72% | +50.86% | 213M | |
| -0.65% | -2.93% | +47.52% | +87.34% | 994B | |
| -0.29% | -3.51% | +48.78% | +63.27% | 640B | |
| +0.83% | +0.26% | +16.76% | +72.52% | 454B | |
| -0.38% | -3.59% | +28.24% | +35.57% | 337B | |
| -0.09% | -13.54% | +10.08% | +26.87% | 261B | |
| -0.43% | -2.48% | -2.07% | +11.48% | 246B | |
| -1.34% | -13.70% | +33.47% | +44.18% | 204B | |
| -3.44% | -7.51% | -20.08% | -59.58% | 190B | |
| -0.75% | -4.82% | +21.94% | +86.55% | 178B | |
| Average | -0.99% | -5.29% | +23.64% | +41.91% | 350.5B | |
| Weighted average by Cap. | -0.51% | -4.42% | +29.87% | +55.71% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PLX Stock
- Company Protalix BioTherapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
